Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.
Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...
Health advocate, author and speaker Dr Fay Karpouzis talks about Lifestyle Medicine, an area which is becoming increasingly ...
As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...
A pneumonia cough may sound deeper or louder than other coughs, and you may notice dryness or phlegm. But it also depends on ...
Other causes of lung cancer are well known, like radon gas exposure, which happens to be fairly prevalent in Appalachia. It’s ...
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
SIOUX CITY (KTIV) - The World Health Organization says chronic obstructive pulmonary disease (COPD) is the third leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback